Clinical Trial Update: SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating SU011248 in combination with irinotecan and cetuximab as a second-line regimen for stage IV colorectal cancer has been ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)
• SU011248

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Colorectal Carcinoma | Phase 1, Phase 2 | Status: TERMINATED